Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YASO GEL Safety and PK Study (PPCM-01)
NCT07281404Phase 1Not yet recruiting
- Sponsor
- Yaso Therapeutics
- Start
- Apr 2026
- Primary completion
- Feb 2028
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of YASO GEL in pregnancy, human immunodeficiency virus infection (HIV) and gonorrhea, sponsored by Yaso Therapeutics. Primary endpoints: Treatment-Emergent Adverse Events at 24 hours and Pharmacokinetics at 24 hours. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
YASO GEL
03
Conditions
pregnancyhuman immunodeficiency virus infection (HIV)gonorrhea
Beyond the preview
Go deeper on NCT07281404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07281404.